Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
Compass Therapeutics (NASDAQ: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapeutics, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company will engage in a fireside chat scheduled for June 5, 2025, from 11:05 to 11:35 AM ET. The presentation will be accessible via webcast and will remain available for replay on Compass' Events page for 90 days following the event.
Compass Therapeutics (NASDAQ: CMPX), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie oncologiche basate su anticorpi, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. La societ脿 parteciper脿 a una tavola rotonda informale programmata per il 5 giugno 2025, dalle 11:05 alle 11:35 ET. La presentazione sar脿 disponibile in diretta streaming e potr脿 essere rivista nella pagina Eventi di Compass per 90 giorni dopo l'evento.
Compass Therapeutics (NASDAQ: CMPX), una empresa biofarmac茅utica en etapa cl铆nica enfocada en el desarrollo de terapias contra el c谩ncer basadas en anticuerpos, ha anunciado su participaci贸n en la pr贸xima Jefferies Global Healthcare Conference. La compa帽铆a participar谩 en una charla informal programada para el 5 de junio de 2025, de 11:05 a 11:35 AM ET. La presentaci贸n estar谩 disponible v铆a webcast y podr谩 ser reproducida en la p谩gina de Eventos de Compass durante 90 d铆as despu茅s del evento.
Compass Therapeutics (NASDAQ: CMPX)電� 頃泊 旮半皹 鞎� 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎� 須岇偓搿�, 雼り皜鞓る姅 Jefferies Global Healthcare Conference鞐� 彀胳棳頃� 鞓堨爼鞛勳潉 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 2025雲� 6鞗� 5鞚� 鞓れ爠 11鞁� 05攵勲秬韯� 11鞁� 35攵�(霃欕秬鞁滉皠)旯岇 鞓堨爼霅� 頇旍儊 雽�頇旍棎 彀胳棳頃� 瓴冹瀰雼堧嫟. 氚滍憸電� 鞗轨簮鞀ろ姼毳� 韱淀暣 鞁滌箔 臧�電ロ晿氅�, 頄夓偓 頉� 90鞚缄皠 Compass 鞚措菠韸� 韼橃澊歆�鞐愳劀 雼れ嫓氤搓赴搿� 鞝滉车霅╇媹雼�.
Compass Therapeutics (NASDAQ : CMPX), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans le d茅veloppement de th茅rapies anticorps contre le cancer, a annonc茅 sa participation 脿 la prochaine Jefferies Global Healthcare Conference. La soci茅t茅 prendra part 脿 une discussion informelle pr茅vue le 5 juin 2025, de 11h05 脿 11h35 (heure de l'Est). La pr茅sentation sera accessible en webcast et restera disponible en replay sur la page 脡v茅nements de Compass pendant 90 jours apr猫s l'茅v茅nement.
Compass Therapeutics (NASDAQ: CMPX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Antik枚rper-basierten Krebstherapeutika spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference bekannt gegeben. Das Unternehmen wird an einem Fireside-Chat teilnehmen, der f眉r den 5. Juni 2025, von 11:05 bis 11:35 Uhr ET geplant ist. Die Pr盲sentation wird per Webcast verf眉gbar sein und kann auf der Veranstaltungsseite von Compass f眉r 90 Tage nach der Veranstaltung erneut angesehen werden.
- None.
- None.
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 3-5, 2025.
Fireside Chat Details
Date: Thursday, June 5, 2025
Time: 11:05 鈥� 11:35 AM ET
Webcast Link:聽
Virtual/Replay availability:聽The fireside chat will be archived for 90 days on Compass鈥櫬犔璨共当�.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. Compass鈥檚 scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company鈥檚 pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at聽.听
Investor Contact
[email protected]
Media Contact
Anna Gifford, Chief of Staff
[email protected]
617-500-8099
FAQ
When is Compass Therapeutics (CMPX) presenting at the Jefferies Global Healthcare Conference 2025?
How long will the CMPX fireside chat replay be available?
What type of company is Compass Therapeutics (CMPX)?
Where can I watch Compass Therapeutics' (CMPX) Jefferies conference presentation?
